Blog
Fannin Partners Secures Grant Funding from NIDA and DoD to Advance Novel PDE4B Inhibitors for Neurological Diseases
Fannin Partners, a Houston-based life science firm developing early-stage therapeutic and medical device technologies, has been awarded two additional grants to further develop its novel phosphodiesterase 4B (PDE4B) inhibitors for neurological conditions.
Goldenrod Therapeutics Announces Abstract Accepted for Presentation at The International Society of Addiction Medicine’s (ISAM) 2022 World Congress Meeting
Meeting Presentation Will Feature Data Demonstrating Promise of Goldenrod Novel Drug in the Treatment of Substance Use Disorders
Fannin In-licenses Anti-Neuroinflammation Small Molecule Drugs from University of Nebraska Medical Center
Fannin has recently licensed a series of compounds from the University of Nebraska Medical Center (UNMC), with plans to tackle neuroinflammation to treat a wide range of disease states.
NIH Awards Goldenrod Therapeutics $350,000 to Develop Novel Treatment for Opioid Use Disorder
Therapeutic Will Be Tested for Potency, Specificity, and Side Effects for the Treatment of Opioid-Use Disorder Under This Proposal